Plasma total cholesterol level as a risk factor for Alzheimer disease the framingham study

Archives of Internal Medicine

Volumn 163, Issue 9, 2003, Pages 1053-1057

  Tan, Zaldy Sy ^a,b   Seshadri, Sudha ^a   Beiser, Alexa ^b   Wilson, Peter W F ^a   Kiel, Douglas P ^a,b   Tocco, Michael ^a   D'Agostino, Ralph B ^c   Wolf, Philip A ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY   (United States)

^c USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHYL BETA CYCLODEXTRIN; MEVINOLIN; STATIN;

ADULT; ALLELE; ALZHEIMER DISEASE; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; FEMALE; GENETIC RISK; GENOTYPE; HUMAN; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; RISK FACTOR; THROMBOCYTE ACTIVATION;

ADULT; AGED; ALZHEIMER DISEASE; APOLIPOPROTEINS E; CHOLESTEROL; FEMALE; GENOTYPE; HUMANS; HYPERCHOLESTEROLEMIA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS;

EID: 0037992873     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.9.1053     Document Type: Article

References (36)

1. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921-923.
2. Mooser V, Helbecque N, Miklossy J, Marcovina SM, Nicod P, Amouyel P. Interactions between apolipoprotein E and apolipoprotein(a) in patients with lateonset Alzheimer's disease. Ann Intern Med. 2000;132:533-537.
3. Hyman BT, Strickland D, Rebeck GW. Role of Low-density lipoprotein receptorrelated protein in β-amyloid metabolism and Alzheimer disease. Arch Neurol. 2000;57:646-650.
4. Hofman A, Ott A, Breteler MMB, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet. 1997; 349:151-154.
5. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000;57:1439-1443.
6. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet. 2000;356:1627-1631.
7. Evans RM, Emsley CL, Gao S, et al. Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans. Neurology. 2000;54:240-242.
8. Notkola IL, Sulkava R, Pekkanen J, et al. Serum total cholesterol, apolipoprotein E ε4 allele, and Alzheimer's disease. Neuroepidemiology. 1998;17:14-20.
9. Romas SN, Tang MX, Berglund L, Mayeux R. APOE genotype, plasma lipids, lipoproteins, and AD in community elderly. Neurology. 1999;53:517-521.
10. Farmer ME, White LR, Kittner SJ, et al. Neuropsychological test performance in Framingham: a descriptive study. Psychol Rep. 1987;60(3, pt 2):1023-1040.
11. Folstein ME, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
12. Bachman DL, Wolf PA, Linn RT, et al. Incidence of dementia and probable Alzheimer's disease in a general population: the Framingham Study. Neurology. 1993; 43:515-519.
13. Wilson PWF, Hoeg JM, D'Agostino RB, et al. Cumulative effects of high cholesterol levels, high blood pressure, and cigarette smoking on carotid stenosis. N Engl J Med. 1997;337:516-522.
14. Abell LL, Levy BB, Brodie BB, Kendall FE. A simplified method for the estimation of total cholesterol in serum and demonstration of its specificity. J Biol Chem. 1952;195:357-366.
15. Lipid Research Clinics Program. Manual of Laboratory Operation. Bethesda, Md: National Institutes of Health; 1974. Publication NIH75-628.
16. Warnick GR, Benderson J, Albers JJ. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem. 1982;28:1379-1382.
17. Cooper GR, Myers GL, Smith SJ, Schlant RC. Blood lipid measurements: variations and practical utility. JAMA. 1992;267:1652-1660.
18. Ordovas JM, Litwack-Klein L, Wilson PW, Schaefer MM, Shaefer EJ. Apolipoprotein E isoform phenotyping methodology and population frequency with identification of apoE1 and apoE5 isoforms. J Lipid Res. 1987;28:371-380.
19. Welty FK, Lahoz C, Tucker KL, Ordovas JM, Wilson PW, Schaefer EJ. Frequency of ApoB and ApoE gene mutations as causes of hypobetalipoproteinemia in the Framingham offspring population. Arterioscler Thromb Vasc Biol. 1998;18:1745-1751.
20. Cobb JL, Wolf PA, Au R, White R, D'Agostino RB. The effect of education on the incidence of dementia and Alzheimer's disease in the Framingham Study. Neurology. 1995;45:1707-1712.
21. Berg L. Clinical Dementia Rating (CDR). Psychopharmacol Bull. 1988;24:637-639.
22. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
23. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;34:939-944.
24. Cupples LA, D'Agostino RB. Some risk factors related to the annual incidence of cardiovascular disease and death using pooled repeated biennial measurements. In: Kannel WB, Wolf PA, Garrison RJ, eds. The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease. Bethesda, Md: National Heart, Lung and Blood Institute; 1987. NIH publication 87-2703, section 34.
25. Wilson PW, Shaefer EJ, Larson MG, Ordova JM. Apolipoprotein E alleles and risk of coronary disease: a meta-analysis. Aterioscler Thromb Vasc Biol. 1996;16:1250-1255.
26. Sparks DL, Liu H, Scheff SW, Coyne CM, Hunsaker JC III. Temporal sequence of plaque formation in the cerebral cortex of non-demented individuals. J Neuropathol Exp Neurol. 1993;52:135-142.
27. Sparks DL, Scheff SW, Hunsacker JC III, Liu H, Landers T, Gross DR. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol. 1994;126:88-94.
28. Kuo YM, Emmerling MR, Bisgaier CL, et al. Elevated low-density lipoprotein in Alzheimer's disease correlates with brain Aβ 1-42 levels. Biochem Biophys Res Commun. 1998;252:711-715.
29. Simons M, Keller P, DeStrooper B, Beyreuther K, Dotti CG, Simons K. Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A. 1998;95:6460-6464.
30. Hallman DM, Boerwinkle E, Saha N, et al. The apolipoprotein E polymorphism: a comparison of allele frequencies and effects in nine populations. Am J Hum Genet. 1991;49:338-349.
31. Shatenstein B, Kergoat MJ, Nadon S. Anthropometric changes over 5 years in elderly Canadians by age, gender and cognitive status. J Gerontol A Biol Sci Med Sci. 2001;56:M483-M488.
32. Wilson PW, Anderson KM, Harris T, Kannel WB, Castelli WP. Determinants of change in total cholesterol and HDL-C with age: the Framingham Study. J Gerontol. 1994;49:M252-M257.
33. Davignon J, Laaksonen R. Low-density lipoprotein-independent effects of statins. Curr Opin Lipidol. 1999;10:543-559.
34. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation. 2000;101:207-213.
35. Hess DC, Demchuk AM, Brass LM, Yatsu FM. HMG-CoA reductase inhibitors (statins): a promising approach to stroke prevention. Neurology. 2000;54:790-796.
36. McGeer EG, McGeer PL. The importance of inflammatory mechanisms in Alzheimer disease. Exp Gerontol. 1998;5:371-378.